RE:RE:AssessmentAnd just an addendum regarding the InMed story. They have been in R&D for 5 years so eating up the share price but finally have commercialized CBC will launch more this year (CBDV, THCV and CBN) so about the turn the corner. Curaleaf has already talked about getting Cannabis derived biosynthetic rare cannbinoids. Raymond James has projected $10B in cannabinoid manufacturing by 2025. Up to $115B by 2040. Even if Inmed captures just 1% of that $10B manufacturing that's $100M. With leading scalability, and manufacturing capability, I believe they can capture much more than 1% of manufacturing. I could easily see 10% = $1B. I also believe Curaleaf is gonna make inroads into this market sooner than later. The only headwinds appear to be the lack of consumer knowledge of the health benefits of rare cannabinoids, but it's evolving at a rapid pace.